ArticleNPJ vaccines2025
Vaccination against COVID-19 and Outcomes in Patients with COVID-19 Infection and Stroke.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We aimed to determine the clinical impact of prior vaccination against Coronavirus Disease 2019 (COVID-19) on COVID-19 infection associated acute ischemic stroke (AIS). Using the TriNetX COVID-19 Research Network, an international electronic health record database, we identified AIS cases admitted between April 1, 2021 and September 30, 2022 that had a COVID-19 diagnosis up to 30 days before hospitalization. The study cohort was divided into two groups: those with and without vaccination against COVID-19. The two groups were matched for demographics, comorbidities, and antithrombotics taken before AIS with 1:1 propensity score matching. Cox proportional hazard analysis was performed to report primary (all-cause mortality) and secondary outcomes at 7 and 30 days after AIS. We identified 3,573 vaccinated (71 ± 12 (mean ± SD) years, 49% females) and 46,329 unvaccinated patients (65 ± 15 years, 45% females) who met the study criteria. After propensity score matching, 3,569 patients were in both groups. Vaccinated individuals had significantly lower rates of all-cause mortality [7 days: 3.3% vs 5.0%; HR = 0.66; 95% CI = 0.52-0.83 and 30 days: 8.2% vs 9.5%; HR = 0.83; 95% CI = 0.71-0.97], intracranial hemorrhage [7 days: 4.1% vs 6.2%; HR = 0.66; 95% CI = 0.53-0.82 and 30 days: 4.5% vs 6.7%; HR = 0.66; 95%CI = 0.53-0.81], venous thromboembolism [7 days: 3.5% vs 7.8%; HR = 0.44; 95% CI = 0.35-0.56 and 30-days: 4.6% vs 8.9%; HR = 0.51; 95% CI = 0.41-0.63] and acute myocardial infarction [7 days: 4.1% vs 7.0%; HR = 0.58; 95% CI = 0.46-0.73 and 30 days: 4.7% vs 7.6%; HR = 0.60; 95% CI = 0.49-0.75)]. Prior vaccination against COVID-19 is associated with reduced rates of all-cause mortality, intracranial hemorrhage, venous thromboembolism, and acute myocardial infarction within 30 days of COVID-19 associated AIS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.